The cancer immunotherapeutics include check-point inhibitor blockade agents (e.g., anti-CTLA4, anti-PD-1, and anti-PD-L1), M2/M1 macrophage repolarizing agents (e.g., resiquimod), cancer antigen-specific chimeric antigen receptor (CAR) T-cells, and adoptive transfer of tumor-infiltrating T-lymphocytes (TILs) to name the few [28,29,30,31,32,33]. This evidence concerns the gene CD274 and cancer.